tert-butyl (4-(trimethylstannyl)phenyl)carbamate | 329020-64-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (4-(trimethylstannyl)phenyl)carbamate
• 英文别名: Tert-butyl 4-(trimethylstannyl)phenylcarbamate；tert-butyl N-(4-trimethylstannylphenyl)carbamate
• CAS: 329020-64-6
• 化学式: C₁₄H₂₃NO₂Sn
• 分子量: 356.052
• InChiKey: OANFMZJSMUVIIE-UHFFFAOYSA-N

物化性质

• 熔点：
  85-86 °C

计算性质

• 辛醇/水分配系数(LogP)：
  3.58
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl (4-(trimethylstannyl)phenyl)carbamate 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(I) bromide 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 72.0h， 生成 2,5-bis(4-aminophenyl)pyrazine
  参考文献：
  名称：

  Ladderlike Oligomers; Intramolecular Hydrogen Bonding, Push-Pull Character, and Electron Affinity

  摘要：

  Symmetrical 2,5-bis(2-aminophenyl)pyrazines have been synthesized by application of the Stille coupling strategy. These cotrimers feature three important properties, namely strong intramolecular hydrogen bonding, push-pull character, and high electron affinity. The presence of intramolecular hydrogen bonds has been confirmed by H-1 NMR, IR spectroscopy, and single crystal X-ray diffraction. The hydrogen bond strength can be increased by substituting the amino groups with stronger electron-withdrawing functionalities. Despite the anticipated enhanced pi -conjugation through planarization, a hypsochromic shift was observed in the UV/Vis spectra, explained by a decrease in push-pull character. The electron affinity of the cotrimers was deduced from the first reduction potentials measured by cyclic voltammetry and is related to the electron-withdrawing character of the amino substituents. The results obtained have been compared with those of the corresponding 4-aminophenyl analogues and show that intramolecular hydrogen bonds can be used to design polymers with enhanced re conjugation as well as a high electron affinity.

  DOI：

  10.1002/1521-3765(20001215)6:24<4597::aid-chem4597>3.0.co;2-4
• 作为产物：
  描述：

  N-Boc-4-碘苯胺 在 三苯基膦钯 六甲基二锡 作用下， 以 1,4-二氧六环 为溶剂， 生成 tert-butyl (4-(trimethylstannyl)phenyl)carbamate
  参考文献：
  名称：

  Biphenyl substituted dipeptide analogs promote release of growth hormone

  摘要：

  已披露某些被确认为替代二肽类似物的化合物，可促进人类和动物体内生长激素的释放。这种特性可用于促进食用动物的生长，使可食肉制品的生产更加高效，在人类中，可增加那些患有正常生长激素分泌不足的人的身高。还披露了含有这些替代二肽类似物作为活性成分的促生长组合物。

  公开号：

  US05726319A1

文献信息

• [EN] ARYL AMIDE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ARYLAMIDE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015006100A1

  公开（公告）日：2015-01-15

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本公开涉及一般可抑制AAK1（适配器相关激酶1）的化合物，包括这些化合物的组合物，以及抑制AAK1的方法。
• Multifunctional Crown-5-calix[4]arene-based Phase-Transfer Catalysts for Aromatic ¹⁸F-Fluorination
  作者：Won Chang Lee、Seok Min Kang、Byung Chul Lee、Sang Eun Kim、Dong Wook Kim

  DOI：10.1021/acs.orglett.0c03604

  日期：2020.12.18

  Methylated bis-triethylene glycolic crown-5-calix[4]arene (M-BTC5A) as a phase-transfer catalyst showed the best performance among other analogues and even conventional Kryptofix 222 in the nucleophilic aromatic 18F-fluorination of diaryliodonium tosylate precursors owing to (i) the efficient release of reactive “naked” [18F]fluoride, (ii) the high stabilization of the precursor in the reaction, and, presumably

  甲基化的双三乙二醇冠-5杯芳烃[4]芳烃（M-BTC5A）作为相转移催化剂，在甲苯磺酸二芳基碘鎓前体的亲核芳族18 F氟化反应中，在其他类似物甚至常规Kryptofix 222中表现出最佳性能（i）有效释放反应性“裸” [ 18 F]氟化物，（ii）反应中前体的高度稳定，以及（iii）前体与K 18 F之间的接触容易/ M-BTC5A复合体通过π-π相互作用促进。使用M-BTC5A以高放射化学收率生产了[ 18 F]氟马西尼。
• Compounds and amyloid probes thereof for therapeutic and imaging uses
  申请人：Tamagnan D. Gilles

  公开号：US20070258887A1

  公开（公告）日：2007-11-08

  The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus. The compounds and amyloid probes of the invention include analogs, salts, pharmaceutical compositions, derivatives, prodrugs, racemic mixtures or tautomeric forms thereof.

  本发明提供了化合物及其淀粉样探针，使得可以通过体内成像诊断AD并定量评估脑部区域中淀粉沉积（斑块）的程度或进展的方法。优选地，本发明的淀粉样探针可以穿过血脑屏障，并区分AD脑与正常脑。可以将淀粉样探针以适量用于体内成像淀粉沉积的方式给患者。本发明的淀粉样探针还可用于检测和定量包括但不限于唐氏综合症、家族性AD和载脂蛋白E4等位基因纯合子在内的疾病中的淀粉沉积。在一个方面，这些化合物可用于治疗或预防包括但不限于AD和2型糖尿病的疾病。该发明的化合物和淀粉样探针包括其类似物、盐、药物组合物、衍生物、前药、外消旋混合物或互变异构体。
• COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES
  申请人：Tamagnan Gilles D.

  公开号：US20100143251A1

  公开（公告）日：2010-06-10

  The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus. The compounds and amyloid probes of the invention include analogs, salts, pharmaceutical compositions, derivatives, prodrugs, racemic mixtures or tautomeric forms thereof.

  本发明提供了化合物及其淀粉样探针，可通过体内成像淀粉样和/或脑部区域的淀粉样沉积物，从而实现诊断AD和量化淀粉样沉积物（斑块）的程度或进展的生前方法。优选地，本发明的淀粉样探针可以穿过血脑屏障，区分AD脑和正常脑。可以向患者施用本发明的淀粉样探针，以适量成像淀粉样沉积物。本发明的淀粉样探针还可用于检测和量化包括但不限于唐氏综合症、家族性AD和载脂蛋白E4等位基因纯合子在内的疾病中的淀粉样沉积物。在一方面，这些化合物可以用于治疗或预防包括但不限于AD和2型糖尿病的疾病。本发明的化合物和淀粉样探针包括其类似物、盐、制药组合物、衍生物、前药、外消旋混合物或其互变异构体。
• ARYL LACTAM KINASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160152621A1

  公开（公告）日：2016-06-02

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本披露通常涉及可以抑制AAK1（适配器相关激酶1）的化合物，包含这些化合物的组合物，以及抑制AAK1的方法。